Andrew Dickinson Divests 2,500 Shares of Gilead Sciences Andrew Dickinson, CFO of Kite Pharma, sold 2,500 shares of Gilead Sciences on March 17, leaving him with 170,674 shares. This sale reflects a broader trend of insider selling, with no insider buys recorded in the past year. Gilead's stock is currently considered overvalued based on its GF Value ratio.1